Idaho Falls site added to RTX-2358 manufacturing plan
PharmaLogic will expand production capacity for Ratio Therapeutics’ Ac-225 RTX-2358 as the FAP-targeted radiopharmaceutical moves through ATLAS clinical testing.
Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration for Ac-225 RTX-2358, Ratio’s FAP-targeted radiopharmaceutical therapy candidate. The agreement broadens clinical supply and future commercialization-readiness work for the investigational therapy.
Under the expanded agreement, PharmaLogic will increase manufacturing capacity at its Idaho Falls therapeutics facility. The companies said the work will include process enhancements intended to support larger-scale, multidose batch production.
RTX-2358 is designed to target fibroblast activation protein-alpha, or FAP, and is labeled with actinium-225. The companies said the expanded manufacturing plan is intended to support ongoing and future clinical studies and position the program for later-stage evaluation in FAP-expressing tumors.
The therapy is being evaluated in the ATLAS trial, an open-label phase 1/2 study in patients with relapsed or refractory soft tissue sarcoma. Ratio has identified the study as NCT07156565.
ATLAS is designed to assess safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of Ac-225 RTX-2358. Patient selection includes assessment of FAP expression with the Cu-64 LNTH-1363S PET imaging agent.
The trial includes an ascending administered-activity phase and an expansion phase. The phase 2 expansion portion is expected to evaluate efficacy and safety in up to 50 patients with soft tissue sarcoma, according to the companies.
PharmaLogic previously supplied the first cohort doses for ATLAS from its Bronx, NY, radiopharmaceutical manufacturing facility. The December 2025 announcement said the collaboration supported Ratio’s advancement of Ac-225 RTX-2358 into clinical testing.
Ratio announced an earlier manufacturing expansion agreement with PharmaLogic in March 2024. That agreement was intended to support development of Ratio’s FAP-targeted radiotherapeutic pipeline.
Companies:Ratio Therapeutics, PharmaLogic
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
uMI Panvivo Mobile joins United Imaging PET lineup
United Imaging used SNMMI 2026 to show new PET/CT and PET/MR systems, including uMI Panvivo Mobile, uMI Panorama GS, and uPMR Zenith.
Ilumira authorization opens EU route for SHINE Lu-177
The EMA-authorized radiopharmaceutical precursor is produced at SHINE’s Cassiopeia facility in Wisconsin for use in radiolabelling carrier medicines.
Virginia theranostics program takes shape with Sentara-BAMF
The joint venture is intended to combine radiopharmaceutical production, molecular imaging, molecular therapy, and clinical trials in a vertically integrated model.
Lead-212 supply pact links Eckert & Ziegler, Thor Medical
hor Medical will initially supply Pb-212 to Eckert & Ziegler for preclinical R&D, while the companies explore broader isotope-production and radiopharmaceutical-manufacturing integration.
Aidoc creates growth post for enterprise AI push
Christopher Young will lead global expansion, partnerships, and enterprise growth after prior healthcare technology roles at BCG and Ascension.
Everlight shifts global teleradiology stack to RadOS
The 5-year agreement will put Sirona Medical’s cloud-native platform across Everlight’s operations in 6 markets, covering PACS, reporting, worklist, archive, and AI workflows.
HCA’s CHCP deal includes imaging CE provider MTMI
HCA Healthcare agreed to acquire CHCP, a Texas allied-health education provider that owns MTMI and offers programs in sonography, radiologic technology, and medical coding.
CBCT perfusion collaboration targets stroke angio suite
Siemens Healthineers and Cercare Medical are pairing Syngo DynaCT Multiphase with Neurosuite to support perfusion imaging during acute stroke interventions.
RC Capital backs Captive’s PET-CT expansion
Captive Radiology said the investment will help scale turnkey imaging programs as demand grows for PET-CT, MRI, and theranostics-related services.
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.